|
Barrie Carter has been Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation since 1992. From 1970 to 1992, he was at the US National Institutes of Health (NIH). From 1982 to 1992 he was Chief of the Laboratory of Molecular and Cellular Biology at the National Institute for Diabetes and Digestive and Kidney Diseases, NIH. Prior to joining the NIH, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. He received his B.Sc. with First Class Honors from the University of Otago, Dunedin, New Zealand in 1966 and his Ph.D. in the Biochemistry Department of the University of Otago Medical School in 1969. Dr. Carter's long-term research interests are in the molecular biology of viruses, development of AAV vectors, gene therapy and the development of therapeutics. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology and is an Associate Editor of Molecular Therapy. From 1995-2000 he was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter has served on a variety of government, scientific, and academic advisory bodies. He currently serves on the External Advisory Committee of the University of Washington School of Public Health and Community Medicine, the Keystone Symposia Scientific Advisory Board, and the Board of Directors of the American Society of Gene Therapy. He has previously served on the Advisory Committee to the Director, NIH and the Scientific Review Committee for Intramural Research, CBER at the US FDA. | 